BMS-986345
Cutaneous T-Cell Lymphoma Refractory
Jonsson Comprehensive Cancer CenterPhase 1/2Active
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Cutaneous T-Cell Lymphoma Refractory cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PREDNISONE TABLETS Shanghai Jiao Tong University School of Medicine | Phase 1/2 | CC |
Duvelisib Jonsson Comprehensive Cancer Center | Phase 1/2 | CC |
Aclarubicin Shanghai Jiao Tong University School of Medicine | Phase 1/2 | CC |
(+)-VINCRISTINE Shanghai Jiao Tong University School of Medicine | Phase 1/2 | CC |
lb1901 Legend Biotech USA Inc | Phase 1 | CC |
Same molecule, other indications
BMS-986345 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →